Eisai stock slumps after Alzheimer’s drug fails to get approval in Europe
Eisai shares fell sharply after its Alzheimer’s drug failed to secure marketing approval in the European Union.
Eisai shares fell sharply after its Alzheimer’s drug failed to secure marketing approval in the European Union.
